NasdaqGS:ZYMEBiotechs
Zymeworks (ZYME) Back In Focus After Q2 Loss, Buyback, And Pipeline Events Raised Valuation Questions
Why Zymeworks Stock Is Back In Focus After Q2 Results
Zymeworks (ZYME) is back on investor watch after reporting a second quarter net loss of US$45.02 million and outlining plans tied to a potential zanidatamab decision and the Theravance Biopharma acquisition.
The company also completed a share repurchase of 1,971,454 shares for US$49.4 million, equal to 2.7% of its stock, which adds another factor for you to consider when assessing Zymeworks today.
See our latest analysis for Zymeworks.
The...